Astellas Pharma Inc
TSE:4503

Watchlist Manager
Astellas Pharma Inc Logo
Astellas Pharma Inc
TSE:4503
Watchlist
Price: 1 521 JPY -0.62% Market Closed
Market Cap: 2.8T JPY
Have any thoughts about
Astellas Pharma Inc?
Write Note

Astellas Pharma Inc
Other Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Astellas Pharma Inc
Other Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Equity CAGR 3Y CAGR 5Y CAGR 10Y
Astellas Pharma Inc
TSE:4503
Other Equity
ÂĄ463.3B
CAGR 3-Years
41%
CAGR 5-Years
37%
CAGR 10-Years
11%
Takeda Pharmaceutical Co Ltd
TSE:4502
Other Equity
ÂĄ2.1T
CAGR 3-Years
66%
CAGR 5-Years
75%
CAGR 10-Years
17%
Daiichi Sankyo Co Ltd
TSE:4568
Other Equity
ÂĄ245.7B
CAGR 3-Years
29%
CAGR 5-Years
22%
CAGR 10-Years
5%
Otsuka Holdings Co Ltd
TSE:4578
Other Equity
ÂĄ237.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
19%
S
Shionogi & Co Ltd
TSE:4507
Other Equity
ÂĄ270.6B
CAGR 3-Years
4 385%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Chugai Pharmaceutical Co Ltd
TSE:4519
Other Equity
ÂĄ2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
6%
No Stocks Found

Astellas Pharma Inc
Glance View

Market Cap
2.7T JPY
Industry
Pharmaceuticals

Astellas Pharma Inc., a beacon in Japan's pharmaceutical landscape, weaves its narrative from a rich tapestry of innovation and strategic acumen. Born from the 2005 merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd., Astellas quickly established itself as a global powerhouse based in Tokyo. The company operates primarily by investing heavily in R&D to drive breakthroughs in life sciences, particularly focusing on therapeutic areas like oncology, urology, immunology, and transplant-related therapies. Through these focal points, Astellas channels its resources to cultivate novel treatments that address unmet medical needs, thereby enhancing the quality of life for patients worldwide. The financial architecture of Astellas Pharma is underpinned by its strategic prowess in expanding its product pipelines and leveraging partnerships to amplify its reach. Revenue generation primarily hinges on its robust product offerings, spearheaded by successful medications such as XTANDI for prostate cancer and Prograf, which aids in organ transplantation outcomes. This diversified product portfolio is complemented by an astute approach to global market penetration, where Astellas not only markets these pharmaceuticals but also strategically collaborates with biotech firms and research institutions to harness cutting-edge technologies. This business model not only propels profitability but also ensures that Astellas remains at the forefront of medical innovation, positioning itself as a pivotal entity within the pharmaceutical industry.

Intrinsic Value
1 752.54 JPY
Undervaluation 13%
Intrinsic Value
Price

See Also

What is Astellas Pharma Inc's Other Equity?
Other Equity
463.3B JPY

Based on the financial report for Sep 30, 2024, Astellas Pharma Inc's Other Equity amounts to 463.3B JPY.

What is Astellas Pharma Inc's Other Equity growth rate?
Other Equity CAGR 10Y
11%

Over the last year, the Other Equity growth was -8%. The average annual Other Equity growth rates for Astellas Pharma Inc have been 41% over the past three years , 37% over the past five years , and 11% over the past ten years .

Back to Top